Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Famitinib as Adjuvant Therapy for NSCLC Patients Without pCR
NCT07890636Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, famitinib in non-small cell lung cancer (NSCLC), sponsored by Ruijin Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
adebrelimabfamitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07890636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890636.